Cyclacel Pharmaceuticals (NASDAQ:CYCC) Posts Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.36, Zacks reports. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Stock Performance

CYCC opened at $0.39 on Friday. Cyclacel Pharmaceuticals has a 1-year low of $0.37 and a 1-year high of $6.00. The stock’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $1.43.

Analysts Set New Price Targets

Several equities research analysts have issued reports on CYCC shares. Roth Capital cut Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. StockNews.com started coverage on Cyclacel Pharmaceuticals in a research note on Friday. They issued a “sell” rating on the stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.